MON-P005
DIABETES SPECIFIC ENTERAL FORMULAS IN ICU M.
Castro1 *, L. M. Horie1 , K. S. Kawamura2 , F. Rascov2 , D. Toledo3 . 1 Gastroenterology, Faculdade de Medicina da USP, Sao Paulo, 2 Nutrition, Pronto Socorro Central, Sao Bernardo, 3 Nutrition, Hospital Albert Einstein, Sao Paulo, Brazil Rationale: Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for hyperglycemic patients is still controversial. This study compares three differents high-protein diabetes-specific formulas to verify the improvement of glycemic control and tolerability. Methods: This was a prospective, open-label, randomized study. The patient groups established according to the high protein formula received were: group A, Glucerna 1.5 (Abbott), B, Diason 1.5 (Nutricia); group C, Novasource GC 1.5 (Nestle). Inclusion criteria were: expected enteral nutrition ≥5 days, baseline glucose >180 mg/dL in the first 48 h. The targeted glucose level was 110–150 mg/dL. Glycemic variability was calculated as the standard deviation, glycemic lability index and coefficient of variation. We collected daily gastrointestinal events (diarrhea and vomiting). Results: A total of 64 patients were consecutively enrolled (A 20, B 24 and C 18). There was no difference in glucose control between the three groups (233 ± 58 vs. 224 ± 46 vs 233 ± 58 IU/ day, p > 0.05). Gastrointestinal events were not different between the groups. Conclusion: In these study, the three diabetes-specific formulas had the same effect in glucose control and gastrointestinal events.
Disclosure of Interest: None declared.
DIABETES SPECIFIC ENTERAL FORMULAS IN ICU M.
Castro1 *, L. M. Horie1 , K. S. Kawamura2 , F. Rascov2 , D. Toledo3 . 1 Gastroenterology, Faculdade de Medicina da USP, Sao Paulo, 2 Nutrition, Pronto Socorro Central, Sao Bernardo, 3 Nutrition, Hospital Albert Einstein, Sao Paulo, Brazil Rationale: Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for hyperglycemic patients is still controversial. This study compares three differents high-protein diabetes-specific formulas to verify the improvement of glycemic control and tolerability. Methods: This was a prospective, open-label, randomized study. The patient groups established according to the high protein formula received were: group A, Glucerna 1.5 (Abbott), B, Diason 1.5 (Nutricia); group C, Novasource GC 1.5 (Nestle). Inclusion criteria were: expected enteral nutrition ≥5 days, baseline glucose >180 mg/dL in the first 48 h. The targeted glucose level was 110–150 mg/dL. Glycemic variability was calculated as the standard deviation, glycemic lability index and coefficient of variation. We collected daily gastrointestinal events (diarrhea and vomiting). Results: A total of 64 patients were consecutively enrolled (A 20, B 24 and C 18). There was no difference in glucose control between the three groups (233 ± 58 vs. 224 ± 46 vs 233 ± 58 IU/ day, p > 0.05). Gastrointestinal events were not different between the groups. Conclusion: In these study, the three diabetes-specific formulas had the same effect in glucose control and gastrointestinal events.
Disclosure of Interest: None declared.
No comments:
Post a Comment